27 Apr Supiroban Ointment (Mupirocin 20mg/g)
| Company name & Address: | registration number | Batch number(s) | Expiry date | Pack size | First release date | Re-call Classification | Recall date |
| Glenmark Pharmaceuticals South Africa (Pty) Ltd
2nd Floor, Building D, Stoneridge Office Park, 8 Greenstone Place, Greenstone, Edenvale, Gauteng, 1609 |
43/20.1.6/0680 |
19242129 |
30 April 2026 |
50g |
30 Aug 2024 |
Class II Type B |
10.Mar.2026 |
Brief description of the problem (reason for recall)
This recall is initiated due to an out of specification result in the Assay and Uniformity test during stability testing.
Advise for health professionals and distributors:
We request that you refrain from selling any of the affected batch of Supiroban and return them to your supplying warehouse or distributor with immediate effect. Glenmark Pharmaceuticals South Africa (Pty) Ltd will collect all your stock which will be credited /replaced. For further product information, please call Glenmark Pharmaceuticals South Africa (Pty) Ltd via our Customer Care line on 011 564 3900.
Proposed action taken and its urgency: A SAHPRA approved recall letter was distributed to all distribution points and the recall process was initiated.
Reporting side effects
Public and healthcare professionals are encouraged to report any side effects after using a health product or after immunisation by using the Med Safety App. Your report will contribute to our monitoring of these health products.